Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Maravai LifeSciences price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Maravai LifeSciences's price to book ratio was 5.5× on Nov 11, 2026, against 2.1× a year earlier. Over the last 5 years it ranged from 0.9× to 31.9×, with a median of 2.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.5× | +3.6 |
| 2025 | Dec 31, 2025 | 1.9× | −0.2 |
| 2024 | Dec 31, 2024 | 2.1× | +0.1 |
| 2023 | Dec 29, 2023 | 2.1× | −4.3 |
| 2022 | Dec 30, 2022 | 6.4× | – |
See a number that looks wrong?